Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses

Nature Chemical Biology

Volumn 8, Issue 2, 2012, Pages 197-204

  Lawrence, Roger ^a   Brown, Jillian R ^b   Al Mafraji, Kanar ^c   Lamanna, William C ^a   Beitel, James R ^b   Boons, Geert Jan ^c   Esko, Jeffrey D ^a   Crawford, Brett E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Zacharon Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; DISACCHARIDE; GLYCOSAMINOGLYCAN; LYSOSOME ENZYME; MONOSACCHARIDE; NONREDUCING END CARBOHYDRATE; TRISACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD ANALYSIS; CHEMICAL COMPOSITION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOLOGY; DEPOLYMERIZATION; DIAGNOSTIC PROCEDURE; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LIQUID CHROMATOGRAPHY; MAROTEAUX LAMY SYNDROME; MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; MOUSE; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PRIORITY JOURNAL; SANFILIPPO SYNDROME; URINALYSIS;

EID: 84862777079     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.766     Document Type: Article

References (43)

1. Neufeld, E.F. & Muenzer, J. The mucopolysaccharidoses. in Metabolic and Molecular Basis of Inherited Disease Vol. 3 (eds. Scriver, C.R. et al.) 3421-3452 (MacGraw-Hill, 2001).
2. Clarke, L.A. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev. Mol. Med. 10, e1 (2008).
3. Beck, M. Therapy for lysosomal storage disorders. IUBMB Life 62, 33-40 (2010).
4. Wei, W., Ninonuevo, M.R., Sharma, A., Danan-Leon, L.M. & Leary, J.A. A comprehensive compositional analysis of heparin/heparan sulfate-derived disaccharides from human serum. Anal. Chem. 83, 3703-3708 (2011).
5. Tomatsu, S. et al. Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J. Inherit. Metab. Dis. 33, 141-150 (2010).
6. Tomatsu, S. et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J. Inherit. Metab. Dis. 28, 743-757 (2005). (Pubitemid 41349262)
7. Fuller, M., Chau, A., Nowak, R.C., Hopwood, J.J. & Meikle, P.J. A defect in exodegradative pathways provides insight into endodegradation of heparan and dermatan sulfates. Glycobiology 16, 318-325 (2006).
8. Fuller, M., Meikle, P.J. & Hopwood, J.J. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 14, 443-450 (2004). (Pubitemid 38744925)
9. Holley, R.J. et al. Mucopolysaccharidosis type I: unique structure of accumulated heparan sulfate and increased N-sulfotransferase activity in mice lacking α-l-iduronidase. J. Biol. Chem. 286, 37515-37524 (2011).
10. Freeze, H.H. Genetic disorders of glycan degradation. in Essentials of Glycobiology (eds. Varki, A. et al.) 567-583 (Cold Spring Harbor Laboratory Press, 2009).
11. Lawrence, R. et al. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J. Biol. Chem. 283, 33674-33684 (2008).
12. Xia, B., Feasley, C.L., Sachdev, G.P., Smith, D.F. & Cummings, R.D. Glycan reductive isotope labeling for quantitative glycomics. Anal. Biochem. 387, 162-170 (2009).
13. Linhardt, R.J. Analysis of glycosaminoglycans with polysaccharide lyases. Curr. Protoc. Mol. Biol. 48, 17.13B1-17.13B16 (2001).
14. Lawrence, R., Lu, H., Rosenberg, R.D., Esko, J.D. & Zhang, L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat. Methods 5, 291-292 (2008). (Pubitemid 351455150)
15. Lamanna, W.C., Lawrence, R., Sarrazin, S. & Esko, J.D. Secondary storage of dermatan sulfate in Sanfilippo disease. J. Biol. Chem. 286, 6955-6962 (2011).
16. Esko, J.D. & Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173 (2001). (Pubitemid 32656238)
17. Sjöberg, I., Fransson, L.A., Matalon, R. & Dorfman, A. Hunter's syndrome: a deficiency of l-idurono-sulfate sulfatase. Biochem. Biophys. Res. Commun. 54, 1125-1132 (1973).
18. O'Brien, J.F., Cantz, M. & Spranger, J. Maroteaux-Lamy disease (mucopolysaccharidosis VI), subtype A: deficiency of a N-acetylgalactosamine-4- sulfatase. Biochem. Biophys. Res. Commun. 60, 1170-1177 (1974).
19. Kimura, A., Hayashi, S. & Tsurumi, K. Chemical structure of urinary dermatan sulfate excreted by a patient with the Hunter syndrome. Tohoku J. Exp. Med. 131, 241-247 (1980). (Pubitemid 10011888)
20. Kimura, A., Hayashi, S., Koseki, M. & Tsurumi, K. Characteristics of urinary glycosaminoglycans excreted by a patient with the Hurler-Scheie compound syndrome. Tohoku J. Exp. Med. 136, 61-66 (1982). (Pubitemid 12154091)
21. Kimura, A., Hayashi, S., Koseki, M., Kochi, H. & Tsurumi, K. Fractionation and characterization of urinary heparan sulfate excreted by patients with Sanfilippo syndrome. Tohoku J. Exp. Med. 144, 227-236 (1984). (Pubitemid 15183026)
22. Toma, L., Dietrich, C.P. & Nader, H.B. Differences in the nonreducing ends of heparan sulfates excreted by patients with mucopolysaccharidoses revealed by bacterial heparitinases: A new tool for structural studies and differential diagnosis of Sanfilippo's and Hunter's syndromes. Lab. Invest. 75, 771-781 (1996).
23. Ramsay, S.L., Meikle, P.J. & Hopwood, J.J. Determination of monosaccharides and disaccharides in mucopolysaccharidoses patients by electrospray ionisation mass spectrometry. Mol. Genet. Metab. 78, 193-204 (2003). (Pubitemid 36332020)
24. King, B., Savas, P., Fuller, M., Hopwood, J. & Hemsley, K. Validation of a heparan sulfate-derived disaccharide as a marker of accumulation in murine mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 87, 107-112 (2006). (Pubitemid 43199866)
25. Mason, K.E., Meikle, P.J., Hopwood, J.J. & Fuller, M. Characterization of sulfated oligosaccharides in mucopolysaccharidosis type IIIA by electrospray ionization mass spectrometry. Anal. Chem. 78, 4534-4542 (2006).
26. Byers, S., Rozaklis, T., Brumfield, L.K., Ranieri, E. & Hopwood, J.J. Glycosaminoglycan accumulation and excretion in the mucopolysaccharidoses: characterization and basis of a diagnostic test for MPS. Mol. Genet. Metab. 65, 282-290 (1998). (Pubitemid 29029544)
27. Bhaumik, M. et al. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9, 1389-1396 (1999). (Pubitemid 30011519)
28. Oguma, T., Tomatsu, S., Montano, A.M. & Okazaki, O. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal. Biochem. 368, 79-86 (2007). (Pubitemid 47058433)
29. Nielsen, T.C., Rozek, T., Hopwood, J.J. & Fuller, M. Determination of urinary oligosaccharides by high-performance liquid chromatography/electrospray ionization-tandem mass spectrometry: application to Hunter syndrome. Anal. Biochem. 402, 113-120 (2010).
30. Peterson, S.B. & Liu, J. Unraveling the specificity of heparanase utilizing synthetic substrates. J. Biol. Chem. 285, 14504-14513 (2010).
31. Kaneiwa, T., Mizumoto, S., Sugahara, K. & Yamada, S. Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence. Glycobiology 20, 300-309 (2010).
32. Shi, X. & Zaia, J. Organ-specific heparan sulfate structural phenotypes. J. Biol. Chem. 284, 11806-11814 (2009).
33. Kresse, H., Paschke, E., von Figura, K., Gilberg, W. & Fuchs, W. Sanfilippo disease type D: deficiency of N-acetylglucosamine-6-sulfate sulfatase required for heparan sulfate degradation. Proc. Natl. Acad. Sci. USA 77, 6822-6826 (1980). (Pubitemid 11163493)
34. He, W., Voznyi Ya, V., Boer, A.M., Kleijer, W.J. & van Diggelen, O.P. A fluorimetric enzyme assay for the diagnosis of Sanfilippo disease type D (MPS IIID). J. Inherit. Metab. Dis. 16, 935-941 (1993). (Pubitemid 23349975)
35. Dean, C.J., Bockmann, M.R., Hopwood, J.J., Brooks, D.A. & Meikle, P.J. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin. Chem. 52, 643-649 (2006).
36. Blanchard, S., Sadilek, M., Scott, C.R., Turecek, F. & Gelb, M.H. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin. Chem. 54, 2067-2070 (2008). (Pubitemid 352774043)
37. Wolfe, B.J. et al. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome). Anal. Chem. 83, 1152-1156 (2011).
38. Duffey, T.A. et al. A tandem mass spectrometry triplex assay for the detection of Fabry, Pompe, and mucopolysaccharidosis-I (Hurler). Clin. Chem. 56, 1854-1861 (2010).
39. Camelier, M.V. et al. Practical and reliable enzyme test for the detection of Mucopolysaccharidosis IVA (Morquio Syndrome type A) in dried blood samples. Clin. Chim. Acta 412, 1805-1808 (2011).
40. Fuller, M. et al. Screening patients referred to a metabolic clinic for lysosomal storage disorders. J. Med. Genet. 48, 422-425 (2011).
41. Zhou, H., Fernhoff, P. & Vogt, R.F. Newborn bloodspot screening for lysosomal storage disorders. J. Pediatr. 159, 7-13.e1 (2011).
42. Komosi ńska-Vassev, K.B., Winsz-Szczotka, K., Kuznik-Trocha, K., Olczyk, P. & Olczyk, K. Age-related changes of plasma glycosaminoglycans. Clin. Chem. Lab. Med. 46, 219-224 (2008).
43. Varki, A. et al. Symbol nomenclature for glycan representation. Proteomics 9, 5398-5399 (2009).